Product Overview

Tabrecta (Capmatinib) is an oral medication used for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) that is positive for MET exon 14 alterations. It works as a selective MET inhibitor, targeting the underlying genetic mutations that drive the cancer's growth.

Indications

Tabrecta is indicated for the treatment of patients with metastatic NSCLC who have a specific genetic mutation known as MET exon 14 alteration.

Dosage and Administration

The recommended dosage of Tabrecta is 150 mg taken orally twice daily, with or without food. It is important to follow your healthcare provider's instructions regarding dosage adjustments and treatment duration.

Possible Side Effects

Common side effects of Tabrecta may include:

• Nausea
• Fatigue
• Edema
• Elevated liver enzymes
• Diarrhea

Precautions

Before taking Tabrecta, inform your healthcare provider about your medical history and any other medications you are taking. Monitor liver function tests regularly during treatment.

Drug Interactions

Tabrecta may interact with other medications. Consult your healthcare provider for a complete list of potential drug interactions.

Storage

Store Tabrecta at room temperature away from moisture and heat. Keep out of reach of children.

Consultation

Always consult your healthcare provider for personalized medical advice and before starting any new treatment.